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Cell therapy: In search of pluripotency
Austin Smith
Cell replacement as a route to treat cellular disease
and injury is currently limited by the availability of 
suitable donor cell populations, but recent results with
mouse embryonic stem cells suggest that isolated
human pluripotent cells could provide a source of cells
for transplantation and gene therapy.
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Injury and disease states are often associated with loss or
death of cells or with cellular dysfunction. In many such
cases, cell replacement is a desirable option for restoration
of tissue function. Bone marrow transfer to replace
leukaemic blood cells is perhaps the best known example
of this approach. Cell transplantation might also provide a
useful way of delivering molecules for genetic therapy,
either gene correction or gene addition. Stem cells derived
from the early embryo might be expandable in culture to
supply specific cell types for regenerative transplants. This
possibility is considered here from both practical and sci-
entific standpoints.
Successful cellular transplantation in general requires the
use of stem cells. A molecular definition of a stem cell
remains elusive. At the cellular level, however, a stem cell
can be defined as a cell that has the capacity both to pro-
duce identical daughter cells — ‘self-renewal’ — and to
produce daughters that are fated to differentiate — ‘com-
mitment’. The potential for self-renewal means that in
principal a stem cell population can be maintained or
expanded indefinitely (Figure 1). 
Self-renewal is central to transplantation for two different
reasons. The first is that it makes possible the long-term
maintenance of grafts of renewing tissues. In tissues that
undergo continuous turnover, such as the haematopoietic
system, functionally mature cells survive for only finite
periods. A red blood cell, for example, has an average life
span of around 100 days. Effective transplantation there-
fore requires both initial reconstitution and ongoing
replenishment of the entire tissue. This can only be
achieved from a transferred stem cell population with the
capacity for long-term self-renewal.
The second reason why self-renewal is so important is that
it enables the large-scale production of cells for transplan-
tation. In the case of ‘cytostatic’ tissues that do not under-
go continuous turnover, such as the brain, transfer of stem
cells should not be necessary for long-term graft mainte-
nance. The mature neurons found in the adult brain are
not readily isolated, however, and in any case they have lit-
tle or no capacity to integrate into a new environment.
Adaptable precursor cells can be obtained from foetal tis-
sue, but this supply is limiting. The isolation and ex vivo
expansion of stem cells is likely to prove crucial, therefore,
for production of immature cells that are competent for
functional incorporation into the adult tissue.
Efforts to isolate, expand and genetically manipulate stem
cells from adult tissues have to date met with only partial
success. An alternative to the primary derivation of tissue-
specific stem cells would be the development of an in vitro
system in which lineage-restricted stem cells could be gen-
erated from a founder stem cell population of human
pluripotent stem cells (HPCs). Pluripotent cells with the
capacity to generate all foetal and adult cell types exist
only in the early embryo and in a particular type of germ
cell tumour, teratocarcinoma. 
HPCs from teratocarcinomas have been established in
culture, but their tumour origin makes them unsuitable
for therapeutic exploitation. In mice, however, the isola-
tion of teratocarcinoma stem cells was followed by the
derivation of non-transformed pluripotent stem cells
directly from embryos [1]. These embryonic stem (ES)
cells are genetically and phenotypically stable if cultured
appropriately, and can be expanded indefinitely. They
can be induced to differentiate in vitro into multiple lin-
eages, including haematopoietic, myogenic, cardiac and
neural cell types. 
Figure 1
Alternative stem cell fates.
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If undifferentiated ES cells are transplanted back into a
mouse embryo they will contribute extensively to the devel-
oping foetus. The resulting chimaeric mice contain ES-cell-
derived functionally differentiated cell types in all tissues.
This paradigm can be extended to transplantation into
adults following in vitro differentiation. Haematopoietic,
cardiac and neuronal derivatives of ES cells have recently
been transferred directly into adult mice with evidence of
functional engraftment [2–4].
The isolation of HPCs analogous to mouse ES cells
would thus create the possibility of generating human
cells for transplantation. To make such a strategy possi-
ble, there are a number of key features that the HPCs
should exhibit. Firstly, they should be pluripotent so that
any desired cell type can be produced in vitro or in vivo.
Secondly, they should be immortal, so that, unlike pri-
mary cells, they undergo unlimited expansion. Thirdly,
they should be phenotypically stable, expressing no
immortalising or transforming genes so as to minimise
the risk of deregulated differentiation and tumour devel-
opment. And fourthly, they should be genetically
tractable so as to facilitate precise genome modifications,
such as the introduction of therapeutic genes or engi-
neering of immunocompatibility.
So what are the prospects of isolating such cells? Until
fairly recently, proven ES cells had only been demon-
strated in rodents. In a very significant development,
however, Thomson and colleagues [5] have succeeded in
establishing several pluripotent cell lines from embryos
of both marmosets and rhesus macaques. Taken in con-
junction with the occurrence in humans of teratocarcino-
mas containing pluripotent stem cells, the evidence sug-
gests that the biological framework may be permissive
for the isolation of HPCs. That this has not been
achieved to date is in part due to the legislative and 
logistical issues involved in research with human embry-
onic material. 
The conventional route to isolation of mouse ES cells is
the culture of pre-implantation blastocysts, which contain
a pluripotential stem cell population, the epiblast. In
many countries, research using pre-implantation stages of
human development is either not permitted or, as in the
United States, is legal but may not be supported by gov-
ernment funds. In other countries, such as the United
Kingdom, legislation allows for certain types of research
under statutory guidelines. Eggs may be donated for
research by couples receiving infertility treatment, or cou-
ples who have completed such treatment and have eggs
remaining in frozen storage. However, a high proportion
of the eggs tend to be abnormal and fail to develop to the
blastocyst stage. The overall availability of human blasto-
cysts is thus a limiting factor. 
An alternative route is to attempt to derive HPCs at later
stages using aborted foetal tissue. In the mouse, pluripo-
tent cells with all the essential features of ES cells can be 
established by culturing primordial germ cells from the
developing foetus [6]. The mechanism by which germ
cells convert to ES cells is obscure, but recent work in
pigs [7] indicates that this phenomenon may be repro-
duced in different mammals. Preliminary studies in
humans suggest that pluripotent cells may be isolated by
this route, although these cells have yet to be charac-
terised in detail [8].
Progress in establishing HPCs is also limited by our
ignorance of the molecular basis of the pluripotent pheno-
type. The ‘POU’ domain transcription factor Oct-4 seems
to be an essential hallmark of a pluripotent stem cell [9],
but the mechanisms that regulate Oct-4 expression are not
known. The continuous propagation of mouse ES cells can
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be sustained by leukaemia inhibitory factor (LIF) or relat-
ed cytokines that activate a second transcription factor,
STAT3 [10]. With the exception of embryos from strain
129 mice, however, provision of LIF alone does not appear
sufficient for the initial generation of ES cells from either
epiblast or germ cells. This may be because additional sig-
nals are required [6,11], and/or because signals derived
from differentiated cell types may induce differentiation or
apoptosis of the stem cells [12]. This is an area in need of
systematic research if we are to develop rational and robust
methods for isolating HPCs. 
A second area in which our present knowledge is inade-
quate is in the generation of pure populations of defined
cell types. Using current protocols, the differentiation of
ES cells is heterogeneous and disorganised, producing a
mixture of cell types. Mixed cell populations are not suit-
able for transplantation, because they can provoke inap-
propriate host responses and may impede access of cells of
interest to the host microenvironment. Furthermore, if
undifferentiated HPCs persist, they may initiate teratoma
development. The characterisation of inductive pathways
that mediate lineage and cell-type-specific differentiation
in the mammalian embryo holds the key to progress. This
may be complemented by techniques for purifying specif-
ic cell types, for example by applying a genetic selection
for expression of a marker gene [4,13]. 
Non-identity with the recipient would be a problem for
transplantation using HPCs from embryonic sources.
Immunosuppression would be required to avoid allogene-
ic rejection. It may prove possible to reduce this problem
by genetic manipulation of histocompatibility loci. A pre-
ferred solution, however, would be to derive HPCs direct-
ly from the patient. Following the demonstration that
nuclei of adult somatic cells can be reprogrammed to allow
cloning — as in the production of the cloned sheep ‘Dolly’
— it is realistic to conceive of generating material for HPC
derivation by nuclear transfer. Indeed in the future it may
become routine for HPCs to be derived from individuals
early in life and stored frozen for later use in regenerative
and repair therapies (Figure 2).
Finally, ethical concerns have been expressed about efforts to
establish HPCs. Such concerns derive from the requirement
to use human embryonic material, as discussed above, and
from the formal possibility that HPCs could be exploited for
human germline modification. With regard to the latter con-
cern, there are already various methods available by which
the human germline could in theory be manipulated, and the
advent of HPCs would not seem to present any significant
new issues. The potential for transforming clinical practice
should therefore outweigh hypothetical scenarios of abuse. 
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